Блокаторы ренин-ангиотензин-альдостероновой системы в лечении больных с висцеральным ожирением и артериальной гипертензией: как преодолеть «феномен ускользания»?
Блокаторы ренин-ангиотензин-альдостероновой системы в лечении больных с висцеральным ожирением и артериальной гипертензией: как преодолеть «феномен ускользания»?
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Список литературы
1. Nguyen G, Delarue F, Burckle C et al. Pivotal role of the renin/prorenin receptors in angiotensin II production and cellular responces to renin. J Clin Invest 2002; 109: 1417–27.
2. Nguyen G, Danser AH. Prorenin and (pro)renin receptor: a review of available data from in vitro studies and experimental modelsin rodents. Exp Physiol 2009; 93: 557–63.
3. Deinum J, Ronn B, Mathiesen E et al. Increase in serum prorenin precedes onset of microalbuminuria in patients with insulin-dependent diabetes mellitus. Diabetologia 1999; 42: 1006–10.
4. Wagner J, Danser AHJ, Derkx FH et al. Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for an intraocular renin-angiotensin system. Br J Ophthalmol 1996; 80: 159–63.
5. Engeli S, Bohnke J, Gorzelniak K et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005; 45: 356–62.
6. Sharma AM, Janke J, Gorzelniak K et al. Angiotensin Blockade Prevents Type 2 Diabetes by Formation of Fat Cells. Hypertension 2002; 40: 609–12.
7. Lastra-Lastra G, Sowers JR, Restrepo-Erazo C et al. Role of Aldosterone and angiotensin II in Insulin Resistance: An Update. Clin Endocrinol 2009; 71: 1–6.
8. Tian F, Luo R, Zhao Z et al. Blockade of the RAS increases plasma adiponectin in subjects with metabolic syndrome and enhances differentiation and adiponectin expression of human preadipocytes. Exp Clin Endocrinol Diabetes 2010; 118 (4): 258–65.
9. Andraws R, Brown DL. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials) Am J Cardiol 2007; 99: 1006–12.
10. Shiigai T, Shichiri M. Late escape from the antiproteinuric effect of ACE inhibitors in nondiabetic renal disease. Am J Kidney Dis 2001; 37: 477–83.
11. Шамхалова М.Ш., Трубицына Н.П., Шестакова М.В. Феномен частичного ускользания блокады ангиотензина II у больных сахарным диабетом типа 2 и диабетической нефропатией. Тер. арх. 2008; 1: 49–52.
12. Kitamura1 N, Takahashi Y, Yamadate S. Angiotensin II receptor blockers decreased blood glucose levels: a longitudinal survey using data from electronic medical records. Cardiovascular Diabetology 2007; 6: 26-31.
13. Sanoski CA, Pharm D. Aliskiren: an oral rennin inhibitor for the treatment of hypertension. Pharmacotherapy 2009; 29: 193–212.
14. Parving HH, Persson F, Lewis JB et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433–46.
15. Masaru I, Harumi K, Yumiko T et al. Direct renin inhibition improved insulin resistance and adipose tissue dysfunction in type 2 diabetic KK-Ay mice. J Hypertens 2010; 28: 1471–81.
16. Dong YF, Liu L, Kataoka K et al. Aliskiren prevents cardiovascular complications and pancreatic injury in a mouse model of obesity and type 2 diabetes. Diabetologia 2010; 53: 180–91.
17. Prescott MF, Boye SW, Le Breton S et al. Antihypertensive efficacy of the direct renin inhibitor aliskiren when added to hydrochlorothiazide treatment in patients with extreme obesity and hypertension. J Am Coll Cardiol 2007; 49 (Suppl. A): 370A.
18. Fogari R, Mugellini A, Preti P et al. Different effects of aliskiren and losartan on fibrinolysis and insulin sensitivity in hypertensive patients with metabolic syndrome. Wolters Kluwer Health 2010; Oral sessions 8B Obesity and metabolic syndrome, e421–8B.01
2. Nguyen G, Danser AH. Prorenin and (pro)renin receptor: a review of available data from in vitro studies and experimental modelsin rodents. Exp Physiol 2009; 93: 557–63.
3. Deinum J, Ronn B, Mathiesen E et al. Increase in serum prorenin precedes onset of microalbuminuria in patients with insulin-dependent diabetes mellitus. Diabetologia 1999; 42: 1006–10.
4. Wagner J, Danser AHJ, Derkx FH et al. Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for an intraocular renin-angiotensin system. Br J Ophthalmol 1996; 80: 159–63.
5. Engeli S, Bohnke J, Gorzelniak K et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005; 45: 356–62.
6. Sharma AM, Janke J, Gorzelniak K et al. Angiotensin Blockade Prevents Type 2 Diabetes by Formation of Fat Cells. Hypertension 2002; 40: 609–12.
7. Lastra-Lastra G, Sowers JR, Restrepo-Erazo C et al. Role of Aldosterone and angiotensin II in Insulin Resistance: An Update. Clin Endocrinol 2009; 71: 1–6.
8. Tian F, Luo R, Zhao Z et al. Blockade of the RAS increases plasma adiponectin in subjects with metabolic syndrome and enhances differentiation and adiponectin expression of human preadipocytes. Exp Clin Endocrinol Diabetes 2010; 118 (4): 258–65.
9. Andraws R, Brown DL. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials) Am J Cardiol 2007; 99: 1006–12.
10. Shiigai T, Shichiri M. Late escape from the antiproteinuric effect of ACE inhibitors in nondiabetic renal disease. Am J Kidney Dis 2001; 37: 477–83.
11. Шамхалова М.Ш., Трубицына Н.П., Шестакова М.В. Феномен частичного ускользания блокады ангиотензина II у больных сахарным диабетом типа 2 и диабетической нефропатией. Тер. арх. 2008; 1: 49–52.
12. Kitamura1 N, Takahashi Y, Yamadate S. Angiotensin II receptor blockers decreased blood glucose levels: a longitudinal survey using data from electronic medical records. Cardiovascular Diabetology 2007; 6: 26-31.
13. Sanoski CA, Pharm D. Aliskiren: an oral rennin inhibitor for the treatment of hypertension. Pharmacotherapy 2009; 29: 193–212.
14. Parving HH, Persson F, Lewis JB et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433–46.
15. Masaru I, Harumi K, Yumiko T et al. Direct renin inhibition improved insulin resistance and adipose tissue dysfunction in type 2 diabetic KK-Ay mice. J Hypertens 2010; 28: 1471–81.
16. Dong YF, Liu L, Kataoka K et al. Aliskiren prevents cardiovascular complications and pancreatic injury in a mouse model of obesity and type 2 diabetes. Diabetologia 2010; 53: 180–91.
17. Prescott MF, Boye SW, Le Breton S et al. Antihypertensive efficacy of the direct renin inhibitor aliskiren when added to hydrochlorothiazide treatment in patients with extreme obesity and hypertension. J Am Coll Cardiol 2007; 49 (Suppl. A): 370A.
18. Fogari R, Mugellini A, Preti P et al. Different effects of aliskiren and losartan on fibrinolysis and insulin sensitivity in hypertensive patients with metabolic syndrome. Wolters Kluwer Health 2010; Oral sessions 8B Obesity and metabolic syndrome, e421–8B.01
Авторы
М.В.Шестакова, И.М.Кутырина
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.